1116433-11-4
Chemical Structure
Itolizumab
Synonym(s): Anti-Human CD6 Recombinant Antibody
- CAS No.: 1116433-11-4
- Formula:N/A
- Molecular Weight:(146.66 kDa)
IUPAC Name: 2-(2-methyl-4-(trifluoromethyl)thiazole-5-carbonyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
SMILES: [Itolizumab]
Biological Activity: Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Itolizumab | ≥99.0% | Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34. [Content Brief]
- [2]. Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031. [Content Brief]
- [3]. Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017 Jul-Aug;62(4):418-421. [Content Brief]
